Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Biofrontera stock

Own Biofrontera stock in just a few minutes.

Biofrontera AG is a biotechnology business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 149 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Biofrontera

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BFRA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Biofrontera share price

Use our graph to track the performance of BFRA stocks over time.

Biofrontera shares at a glance

Information last updated 2021-04-30.
52-week range$4.67 - $41.92
50-day moving average $5.60
200-day moving average $6.86
Wall St. target price$8.00
PE ratio N/A
Dividend yield N/A (0.37%)
Earnings per share (TTM) $-0.76

Buy Biofrontera shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Biofrontera stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biofrontera financials

Revenue TTM $30.3 million
Gross profit TTM $26.8 million
Return on assets TTM -6.11%
Return on equity TTM -150.29%
Profit margin -42.92%
Book value $0.31
Market capitalisation $156.5 million

TTM: trailing 12 months

Shorting Biofrontera shares

There are currently 2,290 Biofrontera shares held short by investors – that's known as Biofrontera's "short interest". This figure is 15.6% down from 2,714 last month.

There are a few different ways that this level of interest in shorting Biofrontera shares can be evaluated.

Biofrontera's "short interest ratio" (SIR)

Biofrontera's "short interest ratio" (SIR) is the quantity of Biofrontera shares currently shorted divided by the average quantity of Biofrontera shares traded daily (recently around 57250). Biofrontera's SIR currently stands at 0.04. In other words for every 100,000 Biofrontera shares traded daily on the market, roughly 40 shares are currently held short.

However Biofrontera's short interest can also be evaluated against the total number of Biofrontera shares, or, against the total number of tradable Biofrontera shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biofrontera's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Biofrontera shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Biofrontera shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biofrontera.

Find out more about how you can short Biofrontera stock.

Biofrontera share dividends

We're not expecting Biofrontera to pay a dividend over the next 12 months.

Biofrontera share price volatility

Over the last 12 months, Biofrontera's shares have ranged in value from as little as $4.67 up to $41.9167. A popular way to gauge a stock's volatility is its "beta".

BFRA.US volatility(beta: 1.47)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.4684. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Biofrontera overview

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.

Frequently asked questions

What percentage of Biofrontera is owned by institutions?
Currently 0.055% of Biofrontera shares are held by institutions.
How many people work for Biofrontera?
Latest data suggests 149 work at Biofrontera.
When does the fiscal year end for Biofrontera?
Biofrontera's fiscal year ends in December.
Where is Biofrontera based?
Biofrontera's address is: Hemmelrather Weg 201, Leverkusen, Germany, 51377
What is Biofrontera's ISIN number?
Biofrontera's international securities identification number is: US09075G1058
What is Biofrontera's CUSIP number?
Biofrontera's Committee on Uniform Securities Identification Procedures number is: 09075G105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site